# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: John Locke (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EN001-SYN
- Date: 2026-03-26
- Fictional facility: St. Posthumous Health Center
- Fictional author: Prudence Hartwell-Osei, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Two-week review of lung function and blood tests; pulmonology consultation today. **S**

## History of present illness

Mr. Locke returns two weeks after his first visit. He has used albuterol once or twice a day, and not since early this morning, six hours before his tests. The open fires in his rooms have not been lit since his first visit; the household has put electric heaters in his study and bedroom, and a HEPA air cleaner runs in each. He has stayed in the country and checks the air quality index each morning. His night cough has eased to two nights a week, but he is still breathless on stairs and hills and wheezes in the cold. He has had no fever, weight loss, night sweats, or blood in his sputum. This morning he had full lung function tests, a six-minute walk, and a CT of the chest, and saw Dr. Nwankwo-Fairfax of pulmonology. **S**

| Element | Detail |
|---|---|
| Reliever use | Albuterol once or twice a day; withheld six hours before testing |
| Exposure | No open fires since intake; electric heating; HEPA air cleaners running; no city trips |
| Symptoms | Night cough two nights a week; breathless on stairs and hills |
| Asthma Control Test | 13, up from 12 |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, night sweats, or weight loss |
| Ears, nose, mouth, and throat | Negative | No nasal blockage, postnasal drip, or loss of smell |
| Respiratory | Positive | Cough at night two nights a week, wheeze in cold air, breathless on exertion; no hemoptysis |
| Cardiovascular | Negative | No chest pain, ankle swelling, or breathlessness lying flat |
| Gastrointestinal | Negative | No heartburn or acid regurgitation |

5 systems reviewed. **S**

## Current medications

- Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 120/74 mmHg; pulse 82 bpm; respirations 18/min; temperature 36.5 °C; oxygen saturation 95% on room air; weight 62.1 kg; BMI 19.6 kg/m². All vital signs are synthetic.

FEV1 before bronchodilator: 2.11 L (low); FVC before bronchodilator: 3.71 L; FEV1/FVC before bronchodilator: 0.57 (low); FEV1 percent predicted (before bronchodilator): 62% (low); FEV1 after bronchodilator: 2.49 L (low); FVC after bronchodilator: 4.02 L; FEV1/FVC after bronchodilator: 0.62 (low); DLCO: 26.4 mL/min/mm[Hg]; FeNO: 41 [ppb] (high); Six-minute walk distance: 430 m (low); Asthma Control Test: 13. All results are synthetic.

## Change since baseline

- Asthma Control Test: 12 at baseline, 13 at this visit **S**

## Immunizations given today

- Pneumococcal conjugate vaccine PCV20 **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, comfortable at rest |
| Respiratory | Prolonged expiration with scattered expiratory wheeze; no crackles; no clubbing; oxygen saturation 95 percent |
| Cardiovascular | Regular rhythm; no murmur; jugular venous pressure not raised; no edema |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Asthma with persistent airflow limitation, type 2 phenotype** (J45.40). Before bronchodilator, FEV1 2.11 L (62 percent predicted) and FEV1/FVC 0.57; after albuterol, FEV1 2.49 L, a rise of 380 mL (11 percent of predicted, a positive response by the ATS/ERS 2022 criterion), with FEV1/FVC 0.62, still below the lower limit of normal (0.67) and below 0.70: airflow limitation that is partly reversible but persists after bronchodilator. FeNO 41 ppb, blood eosinophils 0.46 x 10^3/uL, and IgE 186 IU/mL show type 2 airway inflammation; DLCO 26.4 is normal and the CT shows bronchial wall thickening and air trapping without emphysema or bronchiectasis. Alpha-1 antitrypsin is normal, the interferon-gamma release assay is negative, NT-proBNP is normal, and the chest X-ray is clear. COPD from non-tobacco exposures was considered, because GOLD recognizes COPD in never-smokers exposed to air pollution and solid-fuel smoke and his post-bronchodilator ratio is below 0.70. The features favor asthma: symptoms from his late thirties that vary with season, cold, and smoke, a large bronchodilator response, raised FeNO and eosinophils, no emphysema, and a normal DLCO. The persistent limitation is best explained by long-standing asthma, with pollution and indoor smoke as aggravating causes. Dr. Nwankwo-Fairfax agrees. Because GINA and GOLD advise that anyone with asthma features be treated as asthma, inhaled corticosteroid is essential and a long-acting bronchodilator alone is not safe. **S**
   - Budesonide-formoterol 160/4.5 mcg, two inhalations twice daily and one as needed, no more than 12 a day (GINA track 1, step 4), starting today.
   - Stop albuterol.
   - Inhaler technique taught with his own device and checked by teach-back.
   - Written asthma action plan given; home peak flow twice daily to find his personal best.
   - Pulmonary rehabilitation program, eight weeks, starting next week.
   - Pneumococcal conjugate vaccine PCV20 today.
   - Review in twelve weeks with repeat spirometry and FeNO.
2. **Chronic cough with wheeze and breathlessness** (R05.3). Explained by asthma with persistent airflow limitation; superseded by that diagnosis. Tuberculosis, alpha-1 antitrypsin deficiency, heart failure, and a tumor are excluded. **S**
   - Managed under the asthma problem.
3. **Exposure to air pollution and indoor solid-fuel smoke** (Z77.110). Removing the open fires is the largest change within his control. Fine particles from coal, wood, and traffic aggravate asthma and add to airflow limitation; the WHO 2021 guideline values for PM2.5 are 5 ug/m3 as an annual mean and 15 ug/m3 over 24 hours. **S**
   - Keep the open fires out of use; HEPA air cleaners in his study and bedroom.
   - Check the air quality index each morning; on days of 101 or more (unhealthy for sensitive groups) avoid outdoor exertion and postpone city trips.
   - A well-fitted N95 respirator for unavoidable time outdoors on alert days; walk away from main roads.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test | Every visit | Completed today | 13, up from 12; still very poorly controlled |
| Imaging | Spirometry before and after bronchodilator (FEV1, FVC, FEV1/FVC, bronchodilator response) | At diagnosis, 3 to 6 months after starting treatment, then every 1 to 2 years | Completed today | FEV1 2.11 L before (62 percent predicted) and 2.49 L after albuterol (+380 mL); FVC 3.71 L before and 4.02 L after; FEV1/FVC 0.57 before and 0.62 after, below the lower limit of normal; GLI Global race-neutral equations |
| Imaging | FeNO | When the diagnosis is uncertain, and to monitor inhaled-corticosteroid response | Completed today | 41 ppb, intermediate, before any inhaled corticosteroid |
| Imaging | Diffusing capacity (DLCO) | Once, for persistent airflow limitation | Completed today | 26.4 mL/min/mmHg, normal |
| Imaging | Six-minute walk test | Before and after pulmonary rehabilitation | Completed today | 430 m, below the lower limit of about 480 m; lowest saturation 94 percent |
| Laboratory | Blood eosinophils and total IgE | At diagnosis and at any severe-asthma workup | Completed today | Results from the first visit reviewed today: eosinophils 0.46 x 10^3/uL; IgE 186 IU/mL |
| Laboratory | Alpha-1 antitrypsin level | Once, for persistent airflow limitation | Completed today | Result from the first visit reviewed today: 131 mg/dL, normal |
| Imaging | Chest imaging (X-ray; CT) | Chest X-ray or CT only for atypical features or a suspected complication | Completed today | Chest X-ray at the first visit clear; CT today for persistent airflow limitation in a never-smoker: airway wall thickening and air trapping, no emphysema, bronchiectasis, or nodules |
| Examination | Inhaler technique with his own devices | Every visit | Completed today | Taught today with his new budesonide-formoterol inhaler; correct by teach-back |
| Medication safety | Adherence and reliever use | Every visit | Completed today | Albuterol once or twice a day until today, when it is stopped and replaced by budesonide-formoterol as needed |
| Survey | Exacerbation history (oral corticosteroid courses, emergency visits, admissions in the past 12 months) | Every visit | Completed today | None |
| Self-management | Trigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergens | Every visit | Completed today | Open fires out of use since intake; electric heating; HEPA air cleaners in his study and bedroom; air quality index checked each morning; no city trips since intake |
| Self-management | Smoking and vaping status | Every visit | Completed today | Never smoker; no vaping; no secondhand smoke |
| Self-management | Written asthma action plan | Every visit and after every flare | Completed today | First written plan given today, symptom-based; peak-flow zones to be added once his personal best is known |
| Medication safety | Step-up and step-down assessment | Every visit | Completed today | Started at GINA track 1, step 4 (medium-dose budesonide-formoterol maintenance and reliever) for very poorly controlled asthma with low lung function |
| Examination | Comorbidity surveillance: rhinitis and sinus disease, reflux, obesity, sleep apnea, vocal cord dysfunction, anxiety and depression | At diagnosis and at least yearly | Up to date | Screened at the first visit: no rhinitis, reflux, or snoring; BMI 19.6; PHQ-2 1 |
| Referral | Pulmonary rehabilitation | For persistent breathlessness or reduced exercise capacity | Ordered | Eight-week program starting next week |
| Referral | Pulmonology consultation | For diagnostic uncertainty or persistent airflow limitation | Completed today | Seen today; agrees with asthma with persistent airflow limitation and the plan |
| Self-management | Vaccination status | Yearly | Completed today | PCV20 today; influenza, COVID-19, and RSV vaccines due in the autumn; Tdap up to date |
| Medication safety | Biologic candidacy | When asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and technique | Not indicated | No exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment |

## Goal progress

- Cause of the cough and breathlessness established by the second visit. Outcome by 2026-03-26: Asthma with persistent airflow limitation confirmed by spirometry, FeNO, eosinophils, DLCO, and CT; tuberculosis, alpha-1 antitrypsin deficiency, and heart failure excluded. **S**
- Asthma well controlled (Asthma Control Test 20 or more) with no flare needing oral corticosteroids. In progress; target 2027-03-31. **S**
- No indoor solid-fuel smoke and less outdoor pollution exposure. In progress; target 2027-03-31. **S**
- Six-minute walk distance improved by at least 30 m after pulmonary rehabilitation. In progress; target 2026-06-18. **S**

## Medication changes

- Stopped: Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometry **S**
- Started: Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day **S**

## Guideline basis

- CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026), Aether Forge
- Global Strategy for Asthma Management and Prevention, 2025 update (2025), Global Initiative for Asthma
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020), National Heart, Lung, and Blood Institute (J Allergy Clin Immunol 2020;146(6):1217-1270)
- Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025), Global Initiative for Chronic Obstructive Lung Disease
- Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022), European Respiratory Society and American Thoracic Society
- Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023), American Thoracic Society
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (American Journal of Respiratory and Critical Care Medicine 2023;208(4):e7-e26)
- WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021), World Health Organization
- Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020), European Respiratory Society
- AQI Basics (2026), United States Environmental Protection Agency (AirNow)
- Air Cleaners and Air Filters in the Home (2026), United States Environmental Protection Agency
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention

## Follow-up

- Asthma review in twelve weeks with repeat spirometry and FeNO; call sooner if the reliever is needed more than usual. **S**
- Next scheduled visit 2026-06-18: twelve-week asthma review with repeat spirometry after pulmonary rehabilitation. **S**
